IRCCS Istituto Nazionale Tumori Milano

Milan, MI 20133

0 studies enrolling now · 1 studies all time

What they study most

CANCER,NOS

Studies at this site

• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors — Completed